Clinical Trial Update: A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 study of atezolizumab in combination with an immunotherapy agent (with or without anti-CD20 therapy) for relapsed or refractory non-Hodgkin lymphoma h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lymphoma, Non-Hodgkin | Phase 1 | Status: WITHDRAWN